Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection

Real-world results of nivolumab monotherapy against HCC are lacking in the hepatitis B virus (HBV)-endemic, Asia-Pacific regions. Moreover, heterogeneous responses to immune checkpoint inhibitors have rarely been described in advanced HCC. The aim of this study is to evaluate the efficacy and safety...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Autores principales: Sung, Pil Soo, Jang, Jeong Won, Lee, Jaejun, Lee, Soon Kyu, Lee, Hae Lim, Yang, Hyun, Nam, Hee Chul, Lee, Sung Won, Bae, Si Hyun, Choi, Jong Young, Han, Nam Ik, Yoon, Seung Kew
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7338665/
https://ncbi.nlm.nih.gov/pubmed/32695681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.01043
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares